EDEN Eden Research

EQS-News: Eden granted US EPA regulatory approval

EQS-News: Eden Research plc
Eden granted US EPA regulatory approval

27.09.2022 / 18:06 CET/CEST
The issuer is solely responsible for the content of this announcement.


(, the AIM-quoted company focused on sustainable biopesticides and for use in the global crop protection, and , is pleased to announce that it has received regulatory approval from the , for all five petitions submitted, covering the Company’s three active ingredients (eugenol, geraniol and thymol) and two formulated products (and ).

The EPA approval of Eden’s products and active ingredients will open significant revenue opportunities for Eden, with of approximately €94m for and €189m for . In addition, the Board expects that ultimately the registration of Eden’s developmental insecticide will follow a shortened timeline as it is based upon the now-approved active ingredients. Eden will pursue registration of this new product in due course based upon the outcome of field trials. The total market potential for the insecticide is €237m.

Farmers in the US spend hundreds of millions of dollars every year on products that protect crops from diseases and pests that contribute to lost yields, food waste and inefficient production. Pesticides make up a large percentage of the overall spend on crop inputs. However, regulators around the world have banned a growing number of commonly used conventional chemical pesticide products in recent years, and farmers need to keep up with growing demand for food production. As a result, they are increasingly turning to , like Eden’s and , which are based on natural substances and offer a more , without compromising efficacy, safety, yield or production costs.

Coastal and southern states such as California and Florida will be the initial focus for the use of Eden’s products given the prevalence of high value horticultural crops where Eden’s products currently deliver the highest value. Marketing of the products will commence as soon as possible, subject to state level regulatory approval in these regions, which is expected in the coming months. Assuming timely state-level authorizations, meaningful sales are expected to commence in 2023 following the past several years during which preparations have been made for product launches.

, Chief Executive Officer of Eden Research plc, commented:

“Eden has been at the forefront of accelerating change in the input market for several years, and our authorizations in the US mark the next milestone in this journey, significantly expanding our addressable market to include the second largest food market in the world.

As a small but innovative UK business, we are proud of the impact that Eden can have on the global stage. Despite our size, we export our pioneering products and technologies to Europe, Africa, Australia, and North America, partnering with some of the largest global players in the crop protection industry.

The EPA authorizations are the result of over four years of effort by our experienced regulatory, development and commercial teams who worked tirelessly to ensure that Eden addressed the EPA’s extensive and evolving list of strict requirements.

We are among the very few British crop protection companies to receive approvals for multiple in the US, and we believe we are the smallest company to achieve the ambitious goal of registering three active ingredients and two formulated products at once, thereby opening up one of the world’s most important markets for agricultural inputs”.

Notes to Editors:

Eden Research is the only UK-listed company focused on biopesticides for sustainable agriculture. It develops and supplies innovative biopesticide products and natural microencapsulation technologies to the global crop protection, animal health and consumer products industries.

Eden's products are formulated with terpene active ingredients, based on natural plant defence metabolites. To date, they have been primarily used on high-value fruits and vegetables, improving crop yields and marketability, with equal or better performance when compared with conventional pesticides. Eden has two products currently on the market:

Based on plant-derived active ingredients, Mevalone® is a foliar biofungicide which initially targets a key disease affecting grapes and other high-value fruit and vegetable crops. It is a useful tool in crop defence programmes and is aligned with the requirements of integrated pest management programmes. It is approved for sale in a number of key countries whilst Eden and its partners pursue regulatory clearance in new territories thereby growing Eden's addressable market globally.

Cedroz.

Contact Details

Eden Research plc

Alex Abrey

Company Website


News Source: News Direct


27.09.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at -news.com


Language: English
Company: Eden Research plc
United States
ISIN: GB0001646941
EQS News ID: 1451503

 
End of News EQS News Service

1451503  27.09.2022 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1451503&application_name=news&site_id=research_pool
EN
27/09/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Eden Research

Hybridan Team ... (+2)
  • Hybridan Team
  • Jon Levinson

Duplicate of Hybridan Small Cap Feast: 24/03/2025

Our daily digest of news from UK Small Caps @HybridanLLP 24th March 2025 * A corporate client of Hybridan LLP ** Potential means Intention to Float (ITF) has been announced, or it is a rumour ***Arranged by type of listing and date of announcement ****Alphabetically arranged Share prices and market capitalisations taken from the current price on the day of publication Dish of the day Admissions: On Friday, Wellnex Life Limited (WNX.L) a...

Eden Research: 3 directors

Three Directors at Eden Research bought 1,360,102 shares at between 3.58p and 3.70p. The significance rating of the trade was 63/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the las...

Hybridan Small Cap Feast - 7 November 2024

tatus of this Note and Disclaimer This document has been provided as a general market commentary and is issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as investment advice; a recommendation; an offer to sell; nor solicitation of any offer to buy any security or other financial instrument. Nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. The in...

Hybridan Small Cap Feast - 17 July 2024

17th July 2024 * A corporate client of Hybridan LLP ** Arranged by type of listing and date of announcement *** Alphabetically arranged **** Potential means Intention to Float (ITF) has been announced, or it is a rumour Dish of the day Admissions: None Delistings: FireAngel Safety Technology (FA.L) has left AIM. What’s baking in the oven? ** Potential**** Initial Public Offerings: ITF announced: 8th July 2024: Rome Resources: The Canada-based early-stage resource exploration Company has announce...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion ETF Pathfinder: Actionable ETF research & Ideas

Downgrading Industrials and Materials to Underweight We remain bullish on the S&P 500 and Nasdaq 100 (QQQ) as uptrends remain intact; the formation of new uptrends has been our expectation since late-April (4/30/24 Compass). Near-term we continue to expect to see support at the upside gaps from June 12 and also the 20-day MA and 21-day EMA on the SPX (5375-5408) and QQQ ($467-472). These are strong support levels. Longer-term, we are bullish as long as the SPX is above 5191 and the QQQ is above...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch